Neuropsychiatric disorders and COVID-19

We read with interest the Article by Maxime Taquet and colleagues1Taquet M Geddes JR Husain Luciano S Harrison PJ 6-month neurological psychiatric outcomes in 236 379 survivors of COVID-19 : a retrospective cohort study using electronic health records.Lancet Psychiatry. 2021; 8: 416-427Summary Full Text PDF PubMed Scopus (827) Google Scholar The Lancet Psychiatry that evaluated large population (n=236 379) for complications via analysis diagnostic codes associated notes.1Taquet highest hazard ratios (HRs) reported were myoneural junction or muscle disease (ICD-10 G70–73), HR 5·28 (95% CI 3·71–7·53) after versus influenza 4·52 (3·65–5·59) other respiratory tract infection. These striking findings received little discussion manuscript. incidences specific disorders within this category not presumably available. Some our author group are involved project providing weekly syntheses sequelae COVID-19.2Butler Watson C Rooney A et al.The neurology neuropsychiatry COVID-19. JNNP Blog.https://blogs.bmj.com/jnnp/2020/05/01/the-neurology-and-neuropsychiatry-of-covid-19/Date: 2020Date accessed: April 11, 2021Google have yet found any large-scale publication reporting empirical neuromuscular Hence, we interested to these new findings. speculate critical illness neuromyopathy might partially account Critical polyneuropathy myopathy commonly co-occur, presenting limb weakness, delayed weaning from mechanical ventilation. illnesses, particularly sepsis, including severe COVID-19.3Latronico N Bolton CF myopathy: major cause weakness paralysis.Lancet Neurol. 2011; 10: 931-941Summary (427) Scholar, 4Nasuelli NA Pettinaroli R Godi L al.Critical neuro-myopathy (CINM) focal amyotrophy intensive care unit (ICU) patients SARS-CoV-2: case series.Neurol Sci. 42: 1119-1121Crossref (14) likely adversely affect both short-term long-term patient outcomes, particular concern given very high numbers critically ill COVID-19.5Vanhorebeek I Latronico Van den Berghe G ICU-acquired weakness.Intensive Care Med. 2020; 46: 637-653Crossref (183) Within ICD-10 system, is be coded as specified (G72.8), although there could possibilities coding (G70–73). Other diagnoses, such myasthenia gravis, muscular dystrophy, congenital myopathy, generally less common. higher risk who hospitalised those (HR 7·76 [95% 5·15–11·69]) admitted therapy (11·53 [6·38–20·83]) compatible potentially being an important component category. At face value, finding colleagues indicate complication recommend COVID-19-related investigated more detail. Neuromuscular substantial implications recovery utilisation physical rehabilitation health-care resources. In view, most explanation previously unrecognised, finding. reports honoraria Alberta Psychiatric Association has attended advisory meeting Promentis Pharmaceuticals, outside submitted work. DN principal investigator on NIH-funded randomised trial evaluating nutrition exercise acute failure and, related trial, currently receipt donated amino acid product Baxter Healthcare Corporation equipment loan Reck Medical Devices, All authors declare no competing interests. COVID-19: recordsOur provides evidence morbidity 6 months Risks greatest in, but limited to, had This information help service planning identification research priorities. Complementary designs, prospective cohorts, needed corroborate explain Full-Text Open AccessNeuropsychiatric COVID-19Maxime increased incidence diagnosed (ie, 1) compared two matched control cohorts: 2) infection, 3).1 my opinion, having groups containing shortcoming study, 3 should been transferred 2. Neuropsychiatric – Authors' replyWe thank Elizabeth Charlton colleagues, Josef Finsterer, Ella Burchill their comments Psychiatry.1 COVID-19We rates anxiety diagnosis,1 noted appendix outcome includes F40–F48 ICD-10. Given known occurrence developing post-traumatic stress disorder admission unit,2 wondered if considered re-analysing data assess COVID-19, treated units elsewhere?